Piscione T D, Yager T D, Gupta I R, Grinfeld B, Pei Y, Attisano L, Wrana J L, Rosenblum N D
Division of Nephrology, Hospital for Sick Children, Toronto, Ontario, Canada.
Am J Physiol. 1997 Dec;273(6):F961-75. doi: 10.1152/ajprenal.1997.273.6.F961.
The bone morphogenetic proteins, BMP-2 and OP-1, are candidates for growth factors that control renal branching morphogenesis. We examined their effects in embryonic kidney explants and in the mIMCD-3 cell model of collecting duct morphogenesis (mIMCD-3 cells are derived from the terminal inner medullary collecting duct of the SV40 mouse). Osteogenic protein-1 (OP-1), at a dose of 0.25 nM, increased explant growth by 30% (P = 0.001). In contrast, 100-fold greater concentrations of OP-1 (28 nM) decreased explant growth by 10% (P < 0.001). BMP-2 was entirely inhibitory (maximum inhibition of 7% at 5 nM, P < 0.0004). In an in vitro model for branching morphogenesis utilizing the kidney epithelial cell line, mIMCD-3, low doses of OP-1 (< 0.5 nM) increased the number of tubular structures formed by 28 +/- 5% (P = 0.01), whereas concentrations > 0.5 nM decreased that number by 22 +/- 8% (P = 0.02). All concentrations of BMP-2 (0.05-10 nM) were inhibitory (maximum inhibition at 10 nM of 88 +/- 3%, P < 0.0001). Stimulatory doses of OP-1 increased tubular length (P = 0.003) and the number of branch points/structure (3.2-fold increase, P = 0.0005) compared with BMP-2. To determine the molecular basis for these effects, we demonstrated that BMP-2 is bound to mIMCD-3 cells by the type I serine/threonine kinase receptor, ALK-3, and that OP-1 bound to an approximately 80-kDa protein using ligand-receptor affinity assays. To demonstrate that OP-1 can exert both stimulatory and inhibitory effects within a developing kidney, embryonic explants were treated with agarose beads saturated with 2 microM OP-1. OP-1 decreased the number of ureteric bud/collecting duct branches adjacent to the beads by 58 +/- 1% (P < 0.0001). In contrast, the number of branches in tissue distal to the OP-1 beads was enhanced, suggesting a stimulatory effect at lower doses of OP-1. We conclude that OP-1 and BMP-2 directly control branching morphogenesis and that the effects of OP-1 are dependent on its local concentration within developing kidney tissue.
骨形态发生蛋白BMP - 2和OP - 1是控制肾分支形态发生的生长因子候选物。我们在胚胎肾外植体和集合管形态发生的mIMCD - 3细胞模型(mIMCD - 3细胞源自SV40小鼠的终末内髓集合管)中研究了它们的作用。剂量为0.25 nM的成骨蛋白 - 1(OP - 1)使外植体生长增加30%(P = 0.001)。相比之下,浓度高100倍的OP - 1(28 nM)使外植体生长减少10%(P < 0.001)。BMP - 2完全起抑制作用(5 nM时最大抑制率为7%,P < 0.0004)。在利用肾上皮细胞系mIMCD - 3进行分支形态发生的体外模型中,低剂量的OP - 1(< 0.5 nM)使形成的管状结构数量增加28±5%(P = 0.01),而浓度> 0.5 nM时该数量减少22±8%(P = 0.02)。所有浓度的BMP - 2(0.05 - 10 nM)均起抑制作用(10 nM时最大抑制率为88±3%,P < 0.0001)。与BMP - 2相比,刺激剂量的OP - 1增加了管状长度(P = 0.003)和每个结构的分支点数(增加3.2倍,P = 0.0005)。为了确定这些作用的分子基础,我们证明BMP - 2通过I型丝氨酸/苏氨酸激酶受体ALK - 3与mIMCD - 3细胞结合,并且利用配体 - 受体亲和力测定表明OP - 1与一种约80 kDa的蛋白质结合。为了证明OP - 1在发育中的肾脏内既能发挥刺激作用又能发挥抑制作用,用饱和了2 microM OP - 1的琼脂糖珠处理胚胎外植体。OP - 1使珠子附近的输尿管芽/集合管分支数量减少58±1%(P < 0.0001)。相比之下,OP - 1珠子远端组织中的分支数量增加,表明低剂量的OP - 1有刺激作用。我们得出结论,OP - 1和BMP - 2直接控制分支形态发生,并且OP - 1的作用取决于其在发育中的肾脏组织内的局部浓度。